Creative Planning - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.

Quarter-by-quarter ownership
Creative Planning ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q2 2024$24,107
-37.6%
24,172
-7.4%
0.00%
Q1 2024$38,629
+35.8%
26,1010.0%0.00%
Q4 2023$28,450
-14.0%
26,101
-6.9%
0.00%
Q3 2023$33,091
-24.0%
28,043
-9.2%
0.00%
Q2 2023$43,556
-6.0%
30,8910.0%0.00%
Q1 2023$46,337
+50.6%
30,891
+17.5%
0.00%
Q4 2022$30,760
+2.5%
26,291
-0.3%
0.00%
Q3 2022$30,000
-28.6%
26,368
+0.3%
0.00%
Q2 2022$42,000
+7.7%
26,302
+2.8%
0.00%
Q1 2022$39,000
-32.8%
25,581
+8.5%
0.00%
Q4 2021$58,000
-9.4%
23,581
-7.7%
0.00%
Q3 2021$64,000
-9.9%
25,558
+2.2%
0.00%
Q2 2021$71,000
-74.1%
25,000
-78.5%
0.00%
-100.0%
Q1 2021$274,000
+33.7%
116,4530.0%0.00%
Q4 2020$205,000
+88.1%
116,453
-0.0%
0.00%
Q3 2020$109,000
-9.9%
116,454
-16.0%
0.00%
Q2 2020$121,000
+39.1%
138,697
+31.9%
0.00%
Q1 2020$87,000
-48.5%
105,116
-44.5%
0.00%
-100.0%
Q4 2019$169,000
-15.9%
189,367
-7.7%
0.00%0.0%
Q3 2019$201,000205,1820.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders